Association of TGF-β1 genetic variants with HPV16-positive oropharyngeal cancer

Clinical Cancer Research

Volumn 16, Issue 5, 2010, Pages 1416-1422

  Guan, Xiaoxiang ^a,b   Sturgis, Erich M ^a   Lei, Dapeng ^a,c,d   Liu, Zhensheng ^a   Dahlstrom, Kristina R ^a   Wei, Qingyi ^a   Li, Guojun ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^c SHANDONG UNIVERSITY   (China)

^d BEIJING HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; TRANSFORMING GROWTH FACTOR BETA1; TUMOR MARKER;

ADULT; ARTICLE; BLOOD; CANCER PATIENT; DNA POLYMORPHISM; EUROPEAN AMERICAN; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOSITY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; MAJOR CLINICAL STUDY; MALE; OROPHARYNX CANCER; PRIORITY JOURNAL; RISK; SQUAMOUS CELL CARCINOMA; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; OROPHARYNX TUMOR; PAPILLOMAVIRUS INFECTION; SINGLE NUCLEOTIDE POLYMORPHISM; VIROLOGY;

CARCINOMA, SQUAMOUS CELL; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMAN PAPILLOMAVIRUS 16; HUMANS; MALE; MIDDLE AGED; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRUS INFECTIONS; POLYMORPHISM, SINGLE NUCLEOTIDE; TRANSFORMING GROWTH FACTOR BETA1;

EID: 77649156356     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-2877     Document Type: Article

References (46)

1. Chaturvedi AK, Engels EA, Anderson WF, Gillison ML. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol 2008;26:612-9.
2. Gillison ML, Koch WM, Capone RB, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000;92:709-20.
3. Strome SE, Savva A, Brissett AE, et al. Squamous cell carcinoma of the tonsils: a molecular analysis of HPV associations. Clin Cancer Res 2002;8:1093-100.
4. Ringstrom E, Peters E, Hasegawa M, Posner M, Liu M, Kelsey KT. Human papillomavirus type 16 and squamous cell carcinoma of the head and neck. Clin Cancer Res 2002;8:3187-92.
5. D'Souza G, Kreimer AR, Viscidi R, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007;356: 1944-56.
6. Herrero R, Castellsague X, Pawlita M, et al. Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. J Natl Cancer Inst 2003;95:1772-83.
7. Ernster JA, Sciotto CG, O'Brien MM, et al. Rising incidence of oropharyngeal cancer and the role of oncogenic human papilloma virus. Laryngoscope 2007;117:2115-28.
8. Castellsague X. Natural history and epidemiology of HPV infection and cervical cancer. Gynecol Oncol 2008;110:S4-7.
9. Frazer IH. Interaction of human papillomaviruses with the host immune system: a well evolved relationship. Virology 2009;384:410-4.
10. Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond) 2006;110:525-41.
11. Schiffman M, Kjaer SK. Chapter 2: Natural history of anogenital human papillomavirus infection and neoplasia. J Natl Cancer Inst Monogr 2003;31:14-9.
12. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor β in human disease. N Engl J Med 2000;342:1350-8.
13. Spellberg B, Edwards JE, Jr. Type 1/Type 2 immunity in infectious diseases. Clin Infect Dis 2001;32:76-102.
14. Evans ES, Kocak Z, Zhou SM, et al. Does transforming growth factor-β1 predict for radiation-induced pneumonitis in patients treated for lung cancer? Cytokine 2006;35:186-92.
15. Kong F, Ao X, Wang L, Lawrence TS. The use of blood biomarkers to predict radiation lung toxicity: a potential strategy to individualize thoracic radiation therapy. Cancer Control 2008;15:140-50.
16. Elliott RL, Blobe GC. Role of transforming growth factor β in human cancer. J Clin Oncol 2005;23:2078-93. 17. Derynck R, Akhurst RJ, Balmain A. TGF-β signaling in tumor suppression and cancer progression. Nat Genet 2001;29:117-29.
17. Grainger DJ, Heathcote K, Chiano M, et al. Genetic control of the circulating concentration of transforming growth factor type β1. Hum Mol Genet 1999;8:93-7.
18. Dunning AM, Ellis PD, McBride S, et al. A transforming growth factor β1 signal peptide variant increases secretion in vitro and is associated with increased incidence of invasive breast cancer. Cancer Res 2003;63:2610-5.
19. Kaklamani VG, Baddi L, Liu J, et al. Combined genetic assessment of transforming growth factor-β signaling pathway variants may predict breast cancer risk. Cancer Res 2005;65:3454-61.
20. Awad MR, El-Gamel A, Hasleton P, Turner DM, Sinnott PJ, Hutchinson IV. Genotypic variation in the transforming growth factor-β1 gene: association with transforming growth factor-β1 production, fibrotic lung disease, and graft fibrosis after lung transplantation. Transplantation 1998;66:1014-20.
21. Peralta-Zaragoza O, Bermudez-Morales V, Gutierrez-Xicotencatl L, Alcocer-Gonzalez J, Recillas-Targa F, Madrid-Marina V. E6 and E7 oncoproteins from human papillomavirus type 16 induce activation of human transforming growth factor β1 promoter throughout Sp1 recognition sequence. Viral Immunol 2006;19:468-80.
22. El-Sherif AM, Seth R, Tighe PJ, Jenkins D. Decreased synthesis and expression of TGF-β1, β2, and β3 in epithelium of HPV 16-positive cervical precancer: a study by microdissection, quantitative RT-PCR, immunocytochemistry. J Pathol 2000;192:494-501.
23. Alcocer-Gonzalez JM, Berumen J, Tamez-Guerra R, et al. In vivo expression of immunosuppressive cytokines in human papillomavirus-transformed cervical cancer cells. Viral Immunol 2006;19:481-91.
24. Park JS, Kim EJ, Lee JY, Sin HS, Namkoong SE, Um SJ. Functional inactivation of p73, a homolog of p53 tumor suppressor protein, by human papillomavirus E6 proteins. Int J Cancer 2001;91:822-7.
25. Ji X, Sturgis EM, Zhao C, Etzel CJ, Wei Q, Li G. Association of p73 G4C14-to-A4T14 polymorphism with human papillomavirus type 16 status in squamous cell carcinoma of the head and neck in non-Hispanic whites. Cancer 2009;115:1660-8.
26. Yuan X, Liao Z, Liu Z, et al. Single nucleotide polymorphism at rs1982073:T869C of the TGFβ 1 gene is associated with the risk of radiation pneumonitis in patients with non-small-cell lung cancer treated with definitive radiotherapy. J Clin Oncol 2009;27:3370-8.
27. Llewellyn CD, Johnson NW, Warnakulasuriya KA. Risk factors for squamous cell carcinoma of the oral cavity in young people - a comprehensive literature review. Oral Oncol 2001;37:401-18.
28. Ritchie JM, Smith EM, Summersgill KF, et al. Human papillomavirus infection as a prognostic factor in carcinomas of the oral cavity and oropharynx. Int J Cancer 2003;104:336-44.
29. Kelso A. Th1 and Th2 subsets: paradigms lost?. Immunol Today 1995;16:374-9.
30. Allen JE, Maizels RE. Th1-2: reliable paradigm or dangerous dogma? Immunol Today 1997;18:387-92.
31. El-Omar EM, Rabkin CS, Gammon MD. Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. Gastroenterol 2003;124:1193-201.
32. Akhurst RJ, Derynck R. TGF-β signaling in cancer-a double-edged sword. Trends Cell Biol 2001;11:S44-51.
33. Mills KH, McGuirk P. Antigen-specific regulatory T cells-their induction and role in infection. Semin Immunol 2004;16:107-17.
34. Garba ML, Pilcher CD, Bingham AL, Eron J, Frelinger JA. HIV antigens can induce TGF-β(1)-producing immunoregulatory CD8+ T cells. J Immunol 2002;168:2247-54.
35. Wahl SM. Transforming growth factor β: the good, the bad, and the ugly. J Exp Med 1994;180:1587-90.
36. Fava RA, Olsen NJ, Postlethwaite AE, et al. Transforming growth factor β 1 (TGF-β 1) induced neutrophil recruitment to synovial tissues: implications for TGF-β-driven synovial inflammation and hyperplasia. J Exp Med 1991;173:1121-32.
37. Veldhoen M, Stockinger B. TGFβ1, a "Jack of all trades": the link with pro-inflammatory IL-17-producing T cells. Trends in Immunol 2006; 27:358-61.
38. Clerici M, Merola M, Ferrario E, et al. Cytokine production patterns in cervical intraepithelial neoplasia: association with human papillomavirus infection. J Natl Cancer Inst 1997;89:245-50.
39. Tjiong MY, van der Vange N, ter Schegget JS, Burger MP, ten Kate FW, Out TA. Cytokines in cervicovaginal washing fluid from patients with cervical neoplasia. Cytokine 2001;14:357-60.
40. Clerici M, Shearer GM. The Th1-2 hypothesis of HIV infection: new insights. Immunol Today 1994;15:575-81.
41. Baritaki S, Sifakis S, Huerta-Yepez S, et al. Overexpression of VEGF and TGF-β1 mRNA in Pap smears correlates with progression of cervical intraepithelial neoplasia to cancer: implication of YY1 in cervical tumorigenesis and HPV infection. Int J Oncol 2007;31:69-79.
42. Xu Q, Wang S, Xi L, et al. Effects of human papillomavirus type 16 E7 protein on the growth of cervical carcinoma cells and immunoescape through the TGF-β1 signaling pathway. Gynecol Oncol 2006;101:132-9.
43. Ozbun MA, Meyers C. Transforming growth factor β1 induces differentiation in human papillomavirus-positive keratinocytes. J Virol 1996;70:5437-46.
44. Hasskarl J, Butz K, Whitaker N, Ullmann A, Durst M, Hoppe-Seyler F. Differential cell cycle response of nontumorigenic and tumorigenic human papillomavirus-positive keratinocytes towards transforming growth factor-β1. J Mol Med 2000;78:94-101.
45. Lee DK, Kim BC, Kim IY, Cho EA, Satterwhite DJ, Kim SJ. The human papilloma virus E7 oncoprotein inhibits transforming growth factor-β signaling by blocking binding of the Smad complex to its target sequence. J Biol Chem 2002;277:38557-64.
46. Portugal LG, Goldenberg JD, Wenig BL, et al. Human papillomavirus expression and p53 gene mutations in squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 1997;123:1230-4.